drugset / Trial / NCT04291859

Lu AF28996 in Participants With Parkinson's Disease (PD)

NCT04291859

Phase 1 Completed 57 enrolled H. Lundbeck A/S
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety of Lu AF28996, how well it is tolerated and what the body does to the drug in participants with Parkinson's disease.

Timeline

Start
2020-02-26
Primary completion
2025-10-14
Completion
2026-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lu AF28996 Unknown Oral

Indications